Syndax Pharmaceuticals' stock surged 5.04% during intraday trading on Friday, reflecting strong investor interest in the pharmaceutical company.
The price movement appears to be driven by positive analyst sentiment, with H.C. Wainwright analyst Andres Y. Maldonado reiterating a Buy rating on the company and setting a price target of $40.00. Such analyst endorsements often generate increased investor confidence and buying activity in the market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments